To modulate gut microbiota of IBD patients whose endogenous IgA has the aberrant binding ability to gut bacteria, recombinant mouse IgA can provide a stable supply and ensure safety, which has been difficult with FMT and LBP. This evidence concerns the gene CD79A and inflammatory bowel disease.